In this instance, 4C are referring to cardiac Valve replacement - for regurge (leaking valve) by not replacing the valve, but adding a separate valve structure.
From Memery, the deal with LeM was Cardiocel to be sold for very specific uses....patching congenital cardiac defects, fashioing vein/ artery like structures and repars to the aorta ....and use in cardiac valves was not one of the uses outlines in the deal...so Lem are not in a position to sell Cardiocel for use in valves so I gguess 4C will have to buy from admedus.
Or, thats how I read it......
Happy to be corrected.
- Forums
- ASX - By Stock
- AVR
- Opportunity in TMVR
Opportunity in TMVR, page-5
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$11.68 |
Change
-0.320(2.67%) |
Mkt cap ! $246.9M |
Open | High | Low | Value | Volume |
$11.57 | $11.81 | $11.42 | $152.5K | 13.10K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 116 | $11.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$11.68 | 188 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 116 | 11.500 |
1 | 1000 | 11.400 |
1 | 2 | 11.260 |
1 | 8 | 11.220 |
2 | 1045 | 11.200 |
Price($) | Vol. | No. |
---|---|---|
11.680 | 188 | 1 |
11.700 | 1351 | 1 |
11.900 | 1000 | 1 |
12.000 | 4817 | 1 |
12.400 | 198 | 1 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
RCE
Phase II clinical trial recruitment for R327G topical gel passes halfway, showing promising results against bacterial skin infections
NEWS
New gold and silver soil anomalies uncovered at Black Range, strengthening exploration potential
AVR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online